

# Identification and Treatment of Adolescent Anxiety and Depression – NA/AN/NH/PI

Rebecca S. Daily, MD, DFAPA, DFAACAP

# Epigenetic Factors of Native Populations Mental Health Issues

- High level of epigenetic contributors to Mental Health issues
  - 1.5X higher serious psychological distress than general population
  - 2X more likely to be unemployed
  - 2.5X rate of victimization of whites
  - 3X less likely to have insurance as whites



**Coping with crippling social anxiety through moderately debilitating alcoholism.**

**Coping with moderately debilitating alcoholism through self-enforced social isolation.**

# Anxiety Statistics

- Life prevalence of any anxiety disorder 28.8%
- Onset usually childhood or adolescence
- 50% of affected adult first symptoms before age 11 yrs.
- Worldwide prevalence of Child/Adolescent Anxiety DO 6.5%

# Prevalence of Anxiety Disorders in Adolescents

- Separation Anxiety 2-12.9%
- Panic Disorder
- Agoraphobia 4.5%
- Specific phobia 2.6-9.1%
- Social Anxiety 1.6%
- Acute Traumatic Stress Disorder
- Post Traumatic Stress Disorder 6.3%
- Generalized Anxiety Disorder 2.9-4.6%

# Adolescent Anxiety Symptomatology

Behavioral

Cognitive

Physical



# Major Depressive Disorder in Children

Persistent Depressive Disorder affects approximately:

- 3% age 6-12 years
- 6% age 13-18 years



# Major Depression....

- 50% Adolescents with depression diagnosed before adulthood
- 70% Depression episode #1 recurrence within 5 years
- Male:Female                      1:1 in childhood
- Male:Female                      1:2 in adolescence
- Male:Female                      1:3 at onset of puberty

# Native Youth Depression Comparison

- 2013 CDC YRBS Data
  - 39% Native American
  - 37% Latino
  - 29% Asian
  - 28% African American
  - 27% Caucasian

# Risk List for Adolescent Depression

- Comorbid psychiatric/medical illness
- Parents/siblings with depression
- Trauma exposure/Family/Relationship/Community
- LGBTTQQAA/Sexual abuse
- Substance/Alcohol use
- Stressful life events i.e. breakup with boy/girl friend
- School failure/dropout/pressure
- Bullying/Cyberbullying/Social media
- Sleep Deprivation

# Sleep Deprivation

- 9.5-10 hours required during adolescence for normal growth and function (More for growth spurt)
- Females more vulnerable to sleep deprivation depression than males
- Leads to weight gain/obesity
- Decreased ability to regulate negative emotions, worsened mood
- Males had stronger suicidality association

# Sleep Deprivation can lead to...

- Anxiety
- Irritability
- Poor Emotional Regulation
- Poor Concentration
- Fatigue
- Craving Carbohydrates
- Oppositionality
- Sadness
- Tardiness/Truancy
- Poor Motivation


# Common Symptoms of Depression in Adolescents

- Insomnia
- Poor concentration
- Somatic complaints:
  - headaches
  - stomachaches
- Anxiety
- Binge eating – especially at night
- Self harm
- Substance abuse
- Risk taking
- Fatigue
- Irritability
- Worry
- Social Withdrawal



# Screening for Anxiety & Depression

# No single biomarker has been found for depression



We rely on self-rating and assessment from parents, teachers and clinicians



# When to screen?

- Broad screening
  - Every visit
- Psychosocial risk screening
  - Every visit
- Specific measure screening
  - Positive indicators to broad screening or risk screening
  - Gut instinct should never be ignored

# Risk Factor Screening

- Treatment history
- Trauma history
- Family history
- School issues
- Contagion suicide
- Sexual issues/Pregnancy
- Substance abuse
- Changes in behavior
- Social pressures/Bully
- Community pressures
- Relationship issues
- Sexuality
- Adoption/Foster Care

# Some Screening Tools

## Depression

- Beck Depression Inventory
- Children's Depression Inventory 2 (CDI – 2)
- Center for Epidemiological Studies Depression Scale for Children (CES-DC)
- Patient Health Questionnaire – 9
- Mood Disorders Questionnaire

## Anxiety

GAD – 7 (Generalized Anxiety)

Social Phobia Inventory (SPIN)

Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS)

# Shortcut for Diagnosing Depression

- **S** Sleep disturbance/Somatic complaints
- **I** Loss of Interest/Pleasure
- **G** Guilt
- **E** Energy decrease
- **C** Concentration loss
- **A** Appetite Change/Agitation
- **P** Psychomotor retardation/social withdrawal
- **S** Suicidality/High risk behavior

# Strengths and Difficulties Questionnaire

- Total difficulties
  - Emotional symptoms
  - Conduct problems
  - Hyperactive score
  - Peer problems
  - Prosocial behavior scale
- 
- Parent and Teacher forms
  - Self-report form for Adolescents
  - Online scoring

# American Psychiatric Association DSM - 5

- Available free for clinical use
- Rapid clinical screening and treatment guidance
- Child, Adolescent and Adult screeners
- Cultural considerations section
- <https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/assessment-measures>



# Frequency of Use of Screeners

- To track change over time, complete at regular intervals
- Consistently high scores in a particular domain may indicate significant/problematic symptoms needing further assessment, treatment and follow-up

And then... there  
was nothing.






# Suicide Among Ethnic Youth age 18-24

CDC 2009

Chart Title



# SAD PERSONS Screening Suicide Risk

- S – Sex
- A – Age
- D – Depression
- P – Previous Attempts
- E – Ethanol Abuse
- R – Rational thinking is lost
- S – Social supports lacking
- O – Organized plan
- N – No significant other
- S – Sickness/Stressors

# Approved Medications for Adolescent Anxiety and Depression

Antidepressants Anxiolytics	FDA Approved	Age Range	Dose Range
Fluoxetine	MDD	8+	10-20mg/day
	OCD	7+	10-60mg/day
Fluvoxamine	OCD	8+	8-11 yrs. – 25 – 200mg
			12- 17 yrs. – 25 – 300mg
Sertraline	OCD	6+	6-12 yrs. – 25mg – 200mg
			13-17 yrs. – 50mg – 200mg
Escitalopram	MDD	12+	10-20mg
Duloxetine	GAD	7+	20mg – 60mg/day
Clomipramine	OCD	10+	25mg– 200mg/day or 3mg/kg/day – whichever less

# Oxford Study of Antidepressants for Children and Adolescents, Lancet, June 2016

- 14 Antidepressants
  - 34 trials analyzed
  - 5260 participants aged 9-18 years
  - Ranked by:
    - Efficacy
    - Tolerability
    - Acceptability
    - Associated Serious Harms
- Zhou X, Xie P, Cipriani A, et al.3703

# Lancet study Medications ineffective/Intolerable for Depression in Children/Adolescents 2016

- Venlafaxine – increased suicidal ideation and attempts
- Nortriptyline
- Amitriptyline
- Imipramine
- Desipramine
- Duloxetine
- Paroxetine
- Citalopram
- Mirtazapine
- Sertraline
- Nefazadone
- Escitalopram

## Some details...

- **Least effective**

- Nortriptyline

- **Worst tolerability**

- Imipramine
- Venlafaxine
- Duloxetine

- **Highest suicide risk**

- Venlafaxine

(higher risk than placebo)



Given intolerability issues from this study we have...

## Depression

- Fluoxetine

## Anxiety

- Fluoxetine
- Fluvoxamine
- Clomipramine



# FDA Approval For Children with Anxiety...with notations

## **Generalized Anxiety**

- Duloxetine
  - Worst tolerability,
  - Deadly in overdose

## **Obsessive Compulsive Disorder**

- Clomipramine
  - Deadly in Overdose
- Fluoxetine
- Fluvoxamine
- Sertraline


# FDA Warning

- Issued warning October 2004 antidepressant medications may increase suicidal thoughts/behavior in small number of children and adolescents.
- Response to study in England on paroxetine/venlafaxine where increased suicidal ideation.
- Issued 3 days after action taken in England to prohibit paroxetine/venlafaxine use in children and adolescents.

# More information on FDA warning

- FDA has not prohibited or removed these medications.
- No suicides were reported in the studies leading to the warning.
- After warning issued, over 4 years there was a 44% increase in suicides in countries where warning placed on all antidepressants (USA, Canada, Finland)...most female, most suffocation/strangulation

# Antidepressants



Academy in School Mental Health

Presented by: Sun Life Financial Chair in Adolescent Mental Health



# Side effects:

## Fluoxetine/Fluvoxamine/Sertraline/Clomipramine

- Headache/ Dizziness
  - Stuffy nose
  - Sexual complaints
  - Anxiety
  - Insomnia/Awakening
  - Palpitations
  - Change in appetite
- GI complaints
  - Drowsiness
  - Dry mouth
  - Weight change
  - Increased QTc
  - Flatulence (Clomipramine)
  - Vivid Dreams(escitalopram)

# Fluoxetine

- Depression 10-20mg/day
- Anxiety 10-20mg/day
- Most common SE: Decreased Libido
- Least likely to cause withdrawal symptoms
- Starts about 3 days after last dose taken
  - Nausea
  - Nervousness
  - Insomnia



# Fluvoxamine

- OCD: IR start 25mg q HS

- increase gradually by 25mg as needed

- max 300mg/day

- Divide doses beginning at 50mg

- Most common SE: insomnia

- Withdrawal: within 36 hours of last dose

- Agitation/Irritability

Muscle aches

Anxiety

- Tingling sensation

Suicidal thoughts

Dizziness

- GI distress

Confusion

Mood swings

- Sweating/Hot/Cold flashes

Depersonalization

Insomnia

# Sertraline

- Anxiety: 50mg/day
- may increase gradually
- max 200mg/day
- Most common SE: “Rumbly” stomach, Headache
- Withdrawal: within 36 hours of last dose
  - Dizziness Insomnia/Nightmares Weakness
  - Shaking                      Mood Swings                      Agitation
  - Tingling                      Memory loss                      Suicidal ideation
  - Anger                      Anxiety/Panic                      Nausea/Vomiting/Cramp
  - Confusion                      Vivid dreams                      Poor concentration



# Escitalopram

- Depression: 10mg/day
- Recommend on full stomach, otherwise nausea
- Most common SE: Nausea, Headache, Sexual
- Withdrawal begins within 48 hours of last dose
  - Nausea/ Diarrhea      Anxiety/Irritability      Suicidal thoughts
  - Cramps      Aggression      Stuffy nose
  - Poor concentration      Blurred vision      Sweating
  - Constipation      Crying spells      Insomnia
  - Dizziness      Eye floaters      Depersonalization
  - Headache      Electric shock sensations

# Clomipramine



- Anxiety (OCD):
  - 25mg/day may increase gradually
  - max 3mg/kg/day or 200mg (least amount)
  - Most Common SE: Flatulence, Dry mouth
- Withdrawal: 3 days to 2 weeks after last dose
  - Strange dreams
  - Headache
  - Nausea
  - Stuffy nose
  - Irritability
  - Restlessness

# Duloxetine

- Generalized Anxiety
- 30mg/day x 2 weeks, then may increase to 60mg
- Withdrawal begins about 36 hours after last dose
  - Dizziness                      Nightmares/ Insomnia                      Headache – BAD
  - GI distress                      Anxiety/Irritability/Agitation                      Seizures
  - Tremors                      Paresthesia                      Sleep disruption
  - Sweating                      Hallucinations                      Aggression
  - Fatigue                      Weakness                      Self injury
  - Suicidal ideation/attempts

# Caution

- Serotonin Syndrome
- Overdose
  - More likely (in order) to be with:
    - #1 acetaminophen or ibuprofen
    - #2 SSRI
    - #3 Atypical antipsychotic
    - #4 Antihistamine
  - Death was most likely with Atypical antipsychotics and antidepressants
- Prolonged QT Syndrome
  - If child has history (or family history) of fainting, seizures, arrhythmias or sudden death – check ECG for LQTS



# Therapy

- Cognitive behavior therapy
- Play therapy
- Family therapy
- Exposure therapy
- Individual psychodynamic therapy
- Group therapy



# Cognitive Behavioral Therapy

- Works to change beliefs and interpretations toward a more healthy persona
- Cochrane review of 41 studies, analyzed 26 studies
  - Ages 4-18 yrs.
  - 59.4% remitted from anxiety disorder with CBT (17.5% waitlist controls remitted)
  - No direct comparison between CBT and other therapies
  - After CBT 40% continued to have significant disturbance



# Pearls




# When starting an antidepressant . . .

- FDA warning for Suicidal Ideation
- Close monitoring for suicidal ideation/attempt
- Frequent visits with doctor/nurse/therapist to help with monitoring
- Safety precautions
- There is never a guarantee....when suicidal attempt suspected, hospitalize

Basic Guideline Using FDA  
Indications plus  
Tolerability/Effectiveness Study

Mild to Moderate  
Depression



Therapy

Moderate to Severe  
Depression



Therapy



Fluoxetine

Poor/  
No  
Response

Escitalopram

Poor/  
No  
Resp  
onse

Child/Adolescent  
Psychiatrist

Mild to Moderate  
Generalized Anxiety



Therapy

Moderate to Severe  
Generalized Anxiety




Therapy



Duloxetine

Poor/No  
Response



Child/Adolescent  
Psychiatrist

Mild to Moderate  
Obsessive  
Compulsive Disorder



Therapy


Moderate to Severe  
Obsessive  
Compulsive Disorder




Therapy




Fluoxetine




Fluvoxamine



Child/Adolescent  
Psychiatrist



Sertraline



Clomiprimine

## Also...

- Depression in adolescent can be the first presentation of Bipolar Disorder – there are no medications FDA approved for Adolescents for Bipolar Depression
- If Adolescent becomes more agitated with antidepressant or suicidal ideation occurs (increases).....probable Bipolar Disorder



# Resources and Bibliography

# Helpful Resources

- American Academy of Child & Adolescent Psychiatry [www.aacap.org](http://www.aacap.org)
- Anxiety & Depression Association of America [www.adaa.org](http://www.adaa.org)
- Bipolar Kids [www.bipolarkids.org](http://www.bipolarkids.org)
- Children & Adults with ADHD [www.CHADD.org](http://www.CHADD.org)
- National Alliance for the Mentally Ill [www.NAMI.org](http://www.NAMI.org)
- National Suicide Prevention Lifeline [www.suicidepreventionlifeline.org](http://www.suicidepreventionlifeline.org)
- Zero Suicide [www.zerosuicide.sprc.org](http://www.zerosuicide.sprc.org)

# Bibliography

American Psychiatric Association. (2010). Mental health disparities: American Indians and Alaska Natives. [http://www.integration.samhsa.gov/workforce/mental\\_health\\_disparities\\_american\\_indian\\_and\\_alaskan\\_natives.pdf](http://www.integration.samhsa.gov/workforce/mental_health_disparities_american_indian_and_alaskan_natives.pdf)

Anton-Padaru DT, Teslariu O, Mocanu V. Influence of Sleep on Obesity in Children. Rev Med Chir Soc Med Nat Iasi. 2016 Apr-Jun;120(2):239-43 PMID 27483699

Arnold EM, et al. Sleep Problems, Suicidality and Depression among American Indian Youth. [J Sleep Disord Treat Care](#). 2013 Sep 1;2(3):119.

Baum KT et al., Sleep restriction worsens mood and emotion regulation in adolescents. [J Child Psychol Psychiatry](#). 2014;55(2):180-90. doi: 10.1111/jcpp.12125. Epub 2013 Jul 30.

Bureau of Indian Affairs. (2016). Indian entities recognized and eligible to receive services from the United States Bureau of Indian Affairs. Federal Register, 81(19), 5019-5025 <https://www.gpo.gov/fdsys/pkg/FR-2016-01-29/pdf/2016-01769.pdf>

# Bibliography II

Gone JP, Trimble JE. American Indian and Alaska Native mental health: Diverse perspectives on enduring disparities. *Annual Review of Clinical Psychology*. 2012;8:131–60.

Goodkind JR, et al. PROMOTING HEALING AND RESTORING TRUST:POLICY RECOMMENDATIONS FOR IMPROVING BEHAVIORAL HEALTH CARE FOR AMERICAN INDIAN/ALASKA NATIVE ADOLESCENTS, [Am J Community Psychol](#). 2010 Dec; 46(3-4): 386–394 doi: [10.1007/s10464-010-9347-4](https://doi.org/10.1007/s10464-010-9347-4)

Handbook of Child and Adolescent Anxiety Disorders (Eds.) D. McKay, E.A. Storch, 2011, XIX, 532p. 35 ills., Hardcover ISBN 978-1-4419-7782-3

James AC, James G, Cowdrey FA, et al. Cognitive behavioral therapy for anxiety disorders in children and adolescents. *Cochrane Database Syst Rev* 2013;(6):CD004690.

Liu, David MKI, Alameda Christian K Social Determinants of Health for Native Hawaiian Children and Adolescents, [Hawaii Med J](#). 2011 Nov; 70(11 Suppl 2): 9–14.

[Marzuillo P, et al](#), Acquired long QT syndrome: a focus for the general pediatrician. *Pediatr Emerg Care*. 2014 Apr;30(4):257-61. doi: 10.1097/PEC.000000000000108.

# Bibliography III

[Nestor BA](#)<sup>1</sup>, [Cheek SM](#)<sup>2</sup>, [Liu RT](#)<sup>3</sup>. Ethnic and racial differences in mental health service utilization for suicidal ideation and behavior in a nationally representative sample of adolescents. [J Affect Disord.](#) 2016 Sep 15;202:197-202. doi: 10.1016/j.jad.2016.05.021. Epub 2016 May 27.

Novins DK, Fleming CM, Beals J, Manson SM. Commentary: quality of alcohol, drug, and mental health services for American Indian children and adolescents. *American Journal of Medical Quality.* 2000b;15(4):148–156.

Sheridan DC, et al. Adolescent Suicidal Ingestion: National Trends Over a Decade. [J Adolesc Health.](#) 2017 Feb;60(2):191-195. doi: 10.1016/j.jadohealth.2016.09.012. Epub 2016 Nov 23.

Short MA, Louca M., Sleep deprivation leads to mood deficits in healthy adolescents. [Sleep Med.](#) 2015 Aug;16(8):987-93. doi: 10.1016/j.sleep.2015.03.007. Epub 2015 Apr 16.



# Bibliography IV

Uchida M, et al. A Systematic Evaluation of the QTc Interval and Antidepressants in Youth: An Electronic Health Record Study. [J Dev Behav Pediatr](#). 2015 Jul-Aug;36(6):434-9. doi: 10.1097/DBP.0000000000000188.

Whyte IM. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. [QJM](#). 2003 May;96(5):369-74.

Winsler A, et al., Sleepless in Fairfax: the difference one more hour of sleep can make for teen hopelessness, suicidal ideation, and substance use. [J Youth Adolesc](#). 2015 Feb;44(2):362-78. doi: 10.1007/s10964-014-0170-3. Epub 2014 Sep 2.

# Bibliography - websites

- [www.nctsn.org](http://www.nctsn.org)
- [www.adaa.org](http://www.adaa.org)
- [www.aacap.org](http://www.aacap.org)
- [http://www.bpac.org.nz/resources/other/guides/bpac\\_antidepressant\\_interactions.pdf](http://www.bpac.org.nz/resources/other/guides/bpac_antidepressant_interactions.pdf)
- <http://www.cps.ca/en/tools-outils/condition-specific-screening-tools-and-rating-scales>
- <http://www.fearofstuff.com/phobialist/>
- <http://www.healmyptsd.com/education/post-traumatic-stress-disorder-statistics>



# Bibliography – Websites II

- <https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=39>
- [http://www.nctsn.org/sites/default/files/assets/pdfs/preventing\\_youth\\_suicide.pdf](http://www.nctsn.org/sites/default/files/assets/pdfs/preventing_youth_suicide.pdf)
- <https://www.nimh.nih.gov/health/statistics/prevalence/use-of-mental-health-services-and-treatment-among-children.shtml>
- <http://www.mentalhealthamerica.net/issues/native-american-communities-and-mental-health>
- <https://www.ncbi.nlm.nih.gov/pubmed/27262642>
- [http://www.nicwa.org/children\\_families/](http://www.nicwa.org/children_families/)

# Bibliography – Websites III

- <http://suicidepreventionlifeline.org/wp-content/uploads/2016/08/Suicide-Risk-Assessment-Standards-1.pdf>
- [www.wpic.pitt.edu/research](http://www.wpic.pitt.edu/research)
- <https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/assessment-measures>
- <http://www.robot-hugs.com/about/>
- <https://www.teenrehabcenter.org/co-occurring-disorders/phobias/>